See the DrugPatentWatch profile for tigecycline

Based on the information available, there is some evidence to suggest that prolonged use of tigecycline, an antibiotic commonly used to treat a variety of bacterial infections, may impact liver function tests. A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline was associated with a significant increase in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, which are markers of liver damage, when used for more than 14 days [1].

Another study published in the Journal of Clinical Pharmacy and Therapeutics also reported similar findings, noting that tigecycline use was associated with elevated liver enzymes, particularly after 10 days of therapy [2]. The drug's labeling information also includes warnings about potential hepatotoxicity and the need for monitoring liver function tests in patients receiving prolonged therapy [3].

It is important to note that while these studies suggest a potential link between prolonged tigecycline use and liver function test abnormalities, they do not establish a causal relationship. Further research is needed to better understand the mechanism by which tigecycline may impact liver function and to identify any potential risk factors.

In summary, based on the available information, prolonged use of tigecycline may impact liver function tests, and it is recommended that liver function be monitored in patients receiving prolonged therapy.

Sources:
[1] <https://academic.oup.com/jac/article/65/11/2215/2538747>
[2] <https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpt.12133>
[3] <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s013s014lbl.pdf>